Nasdaq
$3.28▲ 1.96%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $416.8MShares out 1.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 9.21Pre-market26.09.21 13:15filedEFFECTOther#●●●#●●●
Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc.'s registration statement was declared effective by the SEC on September 18, 2026. This filing confirms the official approval of the company's registration documents, completing the legal requirements for future securities offerings or capital raising activities.…more
$3.28+1.96%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.18After-hours26.09.19 05:35424B5Offering
Nautilus Biotechnology, Inc.
Nautilus Biotechnology has entered into an agreement with TD Cowen to conduct an at-the-market (ATM) offering of its common stock for up to $125 million. The proceeds from this offering are intended for general corporate purposes, including the research, development, and commercialization of its proteomics platform. Existing shareholders may face dilution as a result of these new share issuances.…more
$3.28+1.96%vs prev closeView filingShare - 9.11After-hours26.09.12 06:08SCHEDULE 13D/AOwnership
Nautilus Biotechnology, Inc.
AH Bio Fund II, L.P. has filed a SCHEDULE 13D/A regarding its beneficial ownership in Nautilus Biotechnology, Inc. This filing serves to report updates and changes to the fund's existing equity position in the company.…more
$3.28+1.96%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Pre-market26.10.15 21:00#●●●#●●●
Nautilus Biotechnology to Announce Q3 2026 Financial Results
Nautilus Biotechnology announced that it will report its financial results for the third quarter of 2026 on October 27, 2026. The management will host a conference call to discuss the company's performance and business outlook.…more
$3.28+1.96%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.11After-hours26.09.12 05:09
●●●●●●●● ●●●●● ●●●●●●
Nautilus Biotechnology has filed for a $300 million shelf registration, which includes a $125 million at-the-market (ATM) common stock offering. This move indicates potential equity dilution for existing shareholders.…more
$3.28+1.96%vs prev closeShareBenzinga - 9.4Pre-market26.09.04 21:03
●●●●●●●● ●●●●● ●●●●●●
Nautilus Biotechnology published findings in Nature Methods demonstrating the quantification of 130 Tau proteoform groups. The company aims to develop 20 proteoform assays by mid-2028, with an oncology assay scheduled for early access in late 2026.…more
$3.28+1.96%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report